Basic Information
RNALocate ID: | RLID:11002415 |
RNA Symbol: | hsa-miR-361-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-361-5p |
RNA ID: | miRBase:MIMAT0000703 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20976003 |
Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
Method: | Microarray |
Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002009 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01002010 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01002011 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01002012 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01002013 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01002014 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11002414 | Exosome | Serum | 18589210 |
RLID:11002416 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11002417 | Exosome | Renal cancer cells | 21670082 |
RLID:11002418 | Exosome | Brain tissue | 23382797 |
RLID:11002419 | Exosome | Plasma | 23663360 |
RLID:11002420 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11002421 | Exosome | Serum | 25349172 |
RLID:11002422 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11002423 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000117 | Exosome | Blood|Kidney tissue | |
RLID-D:11000406 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-361-5p | Oral squamous cell carcinoma | MNDR-E-MI-43463 |
MNDR | hsa-miR-361-5p | Medulloblastoma | MNDR-E-MI-43464 |
MNDR | hsa-miR-361-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-43465 |
MNDR | hsa-miR-361-5p | Lymphoma | MNDR-E-MI-43466 |
MNDR | hsa-miR-361-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-43467 |
MNDR | hsa-miR-361-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-43468 |
MNDR | hsa-miR-361-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-43469 |
MNDR | hsa-miR-361-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-43470 |
MNDR | hsa-miR-361-5p | Her2-receptor positive breast cancer | MNDR-E-MI-43471 |
MNDR | hsa-miR-361-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-43472 |
MNDR | hsa-miR-361-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-43473 |
MNDR | hsa-miR-361-5p | Dermatomyositis | MNDR-E-MI-43474 |
MNDR | hsa-miR-361-5p | Prostate cancer | MNDR-E-MI-43475 |
MNDR | hsa-miR-361-5p | Gastric cancer | MNDR-E-MI-43476 |
MNDR | hsa-miR-361-5p | Alzheimer disease | MNDR-E-MI-43477 |
MNDR | hsa-miR-361-5p | Intracranial aneurysm | MNDR-E-MI-43478 |
MNDR | hsa-miR-361-5p | Dysautonomia familial | MNDR-E-MI-43479 |
MNDR | hsa-miR-361-5p | Muscular dystrophy duchenne | MNDR-E-MI-43480 |
MNDR | hsa-miR-361-5p | Primary biliary cirrhosis | MNDR-E-MI-43481 |
MNDR | hsa-miR-361-5p | Graves disease | MNDR-E-MI-43482 |
MNDR | hsa-miR-361-5p | Leukemia | MNDR-E-MI-43483 |
MNDR | hsa-miR-361-5p | Cardiovascular disease | MNDR-E-MI-43484 |
MNDR | hsa-miR-361-5p | Carotid stenosis | MNDR-E-MI-43485 |
MNDR | hsa-miR-361-5p | Moyamoya disease | MNDR-E-MI-43486 |
MNDR | hsa-miR-361-5p | Lung cancer | MNDR-E-MI-43487 |
MNDR | hsa-miR-361-5p | Parkinson disease | MNDR-E-MI-43488 |
MNDR | hsa-miR-361-5p | Breast cancer | MNDR-E-MI-43489 |
MNDR | hsa-miR-361-5p | Pituitary neoplasms | MNDR-E-MI-43490 |
MNDR | hsa-miR-361-5p | Pancreatic cancer | MNDR-E-MI-43491 |
MNDR | hsa-miR-361-5p | Melanoma | MNDR-E-MI-43492 |
MNDR | hsa-miR-361-5p | Nephroblastoma | MNDR-E-MI-43493 |
MNDR | hsa-miR-361-5p | Colon cancer | MNDR-E-MI-43494 |
MNDR | hsa-miR-361-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-43495 |
MNDR | hsa-miR-361-5p | Ovarian cancer | MNDR-E-MI-43496 |
MNDR | hsa-miR-361-5p | Prostate adenocarcinoma | MNDR-E-MI-43497 |
MNDR | hsa-miR-361-5p | Carcinoma ductal breast | MNDR-E-MI-43498 |
MNDR | hsa-miR-361-5p | Glioblastoma | MNDR-E-MI-43499 |
MNDR | hsa-miR-361-5p | Glioma | MNDR-E-MI-43500 |
MNDR | hsa-miR-361-5p | Central nervous system lymphoma | MNDR-E-MI-43501 |
MNDR | hsa-miR-361-5p | Chordoma | MNDR-E-MI-43502 |
MNDR | hsa-miR-361-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-43503 |
MNDR | hsa-miR-361-5p | Epilepsy temporal lobe | MNDR-E-MI-43504 |
MNDR | hsa-miR-361-5p | Osteosarcoma | MNDR-E-MI-43505 |
MNDR | hsa-miR-361-5p | Inclusion body myositis | MNDR-E-MI-43506 |
MNDR | hsa-miR-361-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-43507 |
MNDR | hsa-miR-361-5p | Gastric adenocarcinoma | MNDR-E-MI-43508 |
MNDR | hsa-miR-361-5p | Cervical squamous cell carcinoma | MNDR-E-MI-43509 |
MNDR | hsa-miR-361-5p | Pituitary adenoma | MNDR-E-MI-43510 |
MNDR | hsa-miR-361-5p | Lung squamous cell carcinoma | MNDR-E-MI-43511 |
MNDR | hsa-miR-361-5p | Non-small cell lung cancer | MNDR-E-MI-43512 |
MNDR | hsa-miR-361-5p | Lung adenocarcinoma | MNDR-E-MI-43513 |
MNDR | hsa-miR-361-5p | Adrenocortical cancer | MNDR-E-MI-43514 |
MNDR | hsa-miR-361-5p | Thyroid carcinoma | MNDR-E-MI-43515 |
MNDR | hsa-miR-361-5p | Papillary thyroid carcinoma | MNDR-E-MI-43516 |
MNDR | hsa-miR-361-5p | Bladder urothelial carcinoma | MNDR-E-MI-43517 |
MNDR | hsa-miR-361-5p | Pancreatic adenocarcinoma | MNDR-E-MI-43518 |
MNDR | hsa-miR-361-5p | Carcinoma renal cell | MNDR-E-MI-43519 |
MNDR | hsa-miR-361-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-43520 |
MNDR | hsa-miR-361-5p | Clear cell renal cell carcinoma | MNDR-E-MI-43521 |
MNDR | hsa-miR-361-5p | Cholangiocarcinoma | MNDR-E-MI-43522 |
MNDR | hsa-miR-361-5p | Pancreatitis | MNDR-E-MI-43523 |
MNDR | hsa-miR-361-5p | Esophageal cancer | MNDR-E-MI-43524 |
MNDR | hsa-miR-361-5p | Lung small cell carcinoma | MNDR-E-MI-43525 |
MNDR | hsa-miR-361-5p | Encephalopathy bovine spongiform | MNDR-E-MI-43526 |
MNDR | hsa-miR-361-5p | Synovial sarcoma | MNDR-E-MI-43527 |
MNDR | hsa-miR-361-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-43528 |
MNDR | hsa-miR-361-5p | Adenoma | MNDR-E-MI-43529 |
MNDR | hsa-miR-361-5p | Breast invasive carcinoma | MNDR-E-MI-43530 |
MNDR | hsa-miR-361-5p | Hepatocellular carcinoma | MNDR-E-MI-43531 |
MNDR | hsa-miR-361-5p | B-cell lymphoma | MNDR-E-MI-43532 |
MNDR | hsa-miR-361-5p | Rheumatoid arthritis | MNDR-E-MI-43533 |
MNDR | hsa-miR-361-5p | Hodgkin lymphoma | MNDR-E-MI-43534 |
MNDR | hsa-miR-361-5p | Burkitt lymphoma | MNDR-E-MI-43535 |
MNDR | hsa-miR-361-5p | Neuromyelitis optica | MNDR-E-MI-43536 |
MNDR | hsa-miR-361-5p | Colorectal cancer | MNDR-E-MI-43537 |
MNDR | hsa-miR-361-5p | Nasopharynx carcinoma | MNDR-E-MI-43538 |
MNDR | hsa-miR-361-5p | Nasopharyngeal cancer | MNDR-E-MI-43539 |
MNDR | hsa-miR-361-5p | Stroke lacunar | MNDR-E-MI-43540 |
MNDR | hsa-miR-361-5p | Breast cancer her3+ negative | MNDR-E-MI-43541 |
MNDR | hsa-miR-361-5p | Cutaneous squamous cell carcinoma | MNDR-E-MI-43542 |
MNDR | hsa-miR-361-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-43543 |
MNDR | hsa-miR-361-5p | Tubulovillous adenoma | MNDR-E-MI-43544 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCB1 | Homo sapiens | RR00022785 |
TOP